NanoEcho will conduct a preclinical study led by Henrik Thorlacius, Professor of Surgery at Lund University and Chief Physician at Skåne University Hospital in Malmö, in which NanoEcho’s new instrument for detection of lymph nodes with cancer spread will be evaluated. The study will be carried out at Skåne University Hospital in Malmö and will include about 40 patients that will undergo he usual routine standard surgery. Once the cancer is removed from the patient, the surgical preparate will be examined with NanoEcho’s instrument. The result will then be compared with the pathologist’s final microscopic examination.
– My hope for the clinical trial is that we will be able to validate that NanoEcho’s instrument is able to provide high-precision identification of lymph nodes containing cancer cells. If so, we will proceed with further clinical trials, where NanoEcho’s instrument will be evaluated in patients prior to surgery, says Henrik Thorlacius.
– I am very pleased to announce that our joint ethics application has been approved. This entails that we will implement our preclinical trials at two of the major university hospitals in Sweden, in Gothenburg and Skåne. We are currently discussing a start date for the study, and we hope to be able to commence with this study as well during the second quarter. The start date may of course be affected by the prevailing COVID-19 restrictions. I look forward to get started with the study and look with expectation to the outcome, says Linda Persson, NanoEcho’s CEO.
Link to a short video where Henrik Thorlacius tells more about the study.
